Significant scientific papers highlight increasing complexity of honey authentication
Government Chemist team has papers published highlighting increasing complexity of honey authentication
Read MoreNews
To contact the press office please email or call +44 7408 850 514
World Cancer Day 2022
Aristea Anna Leventi is currently completing a PhD between the University of Strathclyde and the National Measurement Laboratory on quantitative bioimaging for cancer diagnostics and biomarker detection.
Read MoreGovernment Chemist contribution recognised as ACMD publishes advice on consumer CBD products
Contributed to advice from Advisory Council on Misuse of Drugs
Read MoreLGC’s site in Berlin wins “most family-friendly workplace” award
Second successive year that we have been awarded the most family-friendly / work-life-balance-oriented employer in the southeast area of Berlin
Read MoreLGC contract awards reinforce its national roles
Renewal of GMOs and feed additives NRL functions supplemented by awarding of new Authorisations roles
Read MoreLGC switches to renewable electricity in Germany
From January 2022, the electricity we purchase for five of our sites in Germany - Augsburg, Berlin, Kulmbach, Luckenwalde and Wesel - will be generated from 100% renewable sources.
Read MoreLGC appoints Vivid Sehgal as Chief Financial Officer
From January 2022, the electricity we purchase for five of our sites in Germany - Augsburg, Berlin, Kulmbach, Luckenwalde and Wesel - will be generated from 100% renewable sources.
Read MoreNew LGC Chair in Measurement Science for Health appointed
LGC has co-sponsored a new Chair in Measurement Science at the University of Strathclyde in Glasgow, UK, to help advance innovation in the medical, food and drink, and high-value manufacturing industries in the UK.
Read MoreLGC reports half year trading in line with expectations
Update for the half year ended 30 September 2021
Read MoreLGC to develop new Berlin site to expand Nucleic Acid Therapeutics capacity
Site will be dedicated to medium to large scale and early to late Phase Clinical GMP manufacturing of Nucleic Acid Therapeutics
Read MoreLGC to develop new Berlin site to expand Nucleic Acid Therapeutics capacity
Site will be dedicated to medium to large scale and early to late Phase Clinical GMP manufacturing of Nucleic Acid Therapeutics
Read MoreLGC’s commitment to carbon net zero
LGC is committing to being carbon net zero by 2050
Read More